Antitrust watchdog plunges Illumina’s megamerger into darkness
Even if the sequencing giant doesn't suffer in the short term from the death of its bid for Pacbio, long-read tech is nipping at its heels.
Illumina bets on Pacific, not nanopores
Illumina’s $1.2bn buy of Pacific Biosciences raises questions about why it shunned another long-read sequencing player, Oxford Nanopore Technologies.
Oxford Nanopore, the disruptive unicorn gunning for Illumina
Can the company's $1.5bn valuation be justified when last year it took just $23.5m in orders?
